These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12839859)

  • 1. Squalene synthase inhibitors.
    Menys VC; Durrington PN
    Br J Pharmacol; 2003 Jul; 139(5):881-2. PubMed ID: 12839859
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
    Ugawa T; Kakuta H; Moritani H; Shikama H
    Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway.
    Do R; Kiss RS; Gaudet D; Engert JC
    Clin Genet; 2009 Jan; 75(1):19-29. PubMed ID: 19054015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of squalene biosynthesis and metabolism.
    Abe I; Tomesch JC; Wattanasin S; Prestwich GD
    Nat Prod Rep; 1994 Jun; 11(3):279-302. PubMed ID: 15200015
    [No Abstract]   [Full Text] [Related]  

  • 7. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
    Charlton-Menys V; Durrington PN
    Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit.
    Tavridou A; Kaklamanis L; Papalois A; Kourounakis AP; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG
    J Pharmacol Exp Ther; 2007 Dec; 323(3):794-804. PubMed ID: 17804677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
    Seiki S; Frishman WH
    Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of inhibition of yeast squalene synthase by substrate analog inhibitors.
    Kalinowski SS; Mookhtiar KA
    Arch Biochem Biophys; 1999 Aug; 368(2):338-46. PubMed ID: 10441385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.
    Nishimoto T; Tozawa R; Amano Y; Wada T; Imura Y; Sugiyama Y
    Biochem Pharmacol; 2003 Dec; 66(11):2133-9. PubMed ID: 14609738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.
    Tavridou A; Manolopoulos VG
    Curr Pharm Des; 2009; 15(27):3167-78. PubMed ID: 19754389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors.
    Griebenow N; Flessner T; Buchmueller A; Raabe M; Bischoff H; Kolkhof P
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2554-8. PubMed ID: 21396815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.
    Ha NT; Lee CH
    Cells; 2020 Oct; 9(11):. PubMed ID: 33113804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removing the golden coat of Staphylococcus aureus.
    Daum RS
    N Engl J Med; 2008 Jul; 359(1):85-7. PubMed ID: 18596277
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential role of nonstatin cholesterol lowering agents.
    Trapani L; Segatto M; Ascenzi P; Pallottini V
    IUBMB Life; 2011 Nov; 63(11):964-71. PubMed ID: 21990243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents.
    Kourounakis AP; Katselou MG; Matralis AN; Ladopoulou EM; Bavavea E
    Curr Med Chem; 2011; 18(29):4418-39. PubMed ID: 21864285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors.
    Ishihara T; Kakuta H; Moritani H; Ugawa T; Yanagisawa I
    Bioorg Med Chem; 2004 Nov; 12(22):5899-908. PubMed ID: 15498666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.